Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.

ABSTRACT:

Aim

The objective of the study was to detect changes in quality of life (QoL) in metastatic breast cancer patients treated with metronomic chemotherapy with daily low doses of cyclophosphamide and celecoxib.

Material & methods

Patients included in a Phase II trial, treated with metronomic cyclophosphamide and celecoxib were included in the QoL study. Assessment of QoL was carried out every 2 months by the Functional Assessment of Cancer Therapy Breast (FACT-B) questionnaire, Brief Pain Inventory and Eastern Cooperative Oncologic Group scale. Data were analyzed at three time points: baseline (BL); middle of treatment (MT); and end of treatment (ET).

Results

A total of 20 patients were included. All patients were heavily pretreated. Treatment showed a good and safe ther

SUBMITTER: Perroud HA 

PROVIDER: S-EPMC4976839 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature